Argenx to Buy Forte Biosciences for $2.2 Billion
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Argenx to Buy Forte Biosciences for $2.2 Billion" is generating significant coverage in the Business category, with 10 articles from 10 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo Finance, STAT, GlobeNewswire and Investing.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 48d ago.
Quick answers
Why is "Argenx to Buy Forte Biosciences for $2.2 Billion" trending?
Because 10 independent news sources published 10 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (10)
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline Yahoo Finance · 51d ago
- Argenx to buy autoimmune-focused Forte Biosciences for $2.2B STAT · 51d ago
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline GlobeNewswire · 51d ago
- TD Cowen downgrades Forte Biosciences stock rating on Argenx deal Investing.com · 51d ago
- Argenx to acquire Forte Biosciences for $2.2B Axios · 51d ago
- TD Cowen downgrades Forte Biosciences stock rating on Argenx deal By Investing.com Investing.com Canada · 51d ago
- argenx to buy Forte Bio for $2.2B in immunology push FirstWord Pharma · 51d ago
- Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B Endpoints News · 51d ago
- Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug Fierce Biotech · 51d ago
- Argenx to Buy Forte Biosciences for $2.2 Billion WSJ · 51d ago
Topics
Related trends
Trump Approves $2.8 Billion Arms Sale to Israel, Including 40,000 One-Ton Bombs
3 news sources are covering this World story right now — PULSE is tracking how fast it spreads.
Trump Is Reportedly Sending Israel $2.8 Billion in Bombs. You’re Paying for Them
3 news sources are covering this World story right now — PULSE is tracking how fast it spreads.
Gates Foundation Pledges $1 Billion to Combat A.I. Inequality
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Z.AI Plans $5.0 Billion Fundraising to Fuel AI Expansion
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Nvidia May Put $10 Billion Into Anthropic’s $2 Trillion IPO. Amazon Already Has Much More Riding on It
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 Incredible High-Growth Stocks to Buy With $10,000 Right Now
Financial publications spotlight high-growth stock picks, featuring selections for long-term holding and potential market opportunities.